Nova Patents
EP0900568A3

AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy

Abstract

The invention relates to a method of treating dyskinesias associated with dopamine agonist therapy in a mammal which comprises administering to said mammal a compound, as defined herein, which is an antagonist of the AMPA receptor. Dopamine agonist therapy, as referred to in the present invention, is generally used in the treatment of a central nervous system disorder such as Parkinson's disease.

Term

Term ended

Projected expiry passed 4 September 2018, 8.1 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

Every citation, both waysCites: the store holds 6 of 7

Citations
DocumentRelationOfficeCategoryCited duringRelevant claims
US4183931ACitesUnited States of AmericaASearch report1-7
WO9213535A1CitesWorld Intellectual Property Organization (WIPO)ASearch report1-7
WO9308173A1CitesWorld Intellectual Property Organization (WIPO)ASearch report1-7
WO9521842A1CitesWorld Intellectual Property Organization (WIPO)ASearch report1-7
WO9608493A1CitesWorld Intellectual Property Organization (WIPO)ASearch report1-7
WO9743276A1CitesWorld Intellectual Property Organization (WIPO)DAPASearch report1-7
KOE B K ET AL: "ENHANCEMENT OF BENZODIAZEPINE BINDING BY METHAQUALONE AND RELATED QUINAZOLINONES", DRUG DEVELOPMENT RESEARCH,US,NEW YORK, NY, vol. 7, no. 3, 1986, pages 255 - 268, XP002064447, ISSN: 0272-4391Non-patent––Search report–
LOSCHMANN P. ET AL: "Synergism of the AMPA-Antagonist NBQX and the NMDA-Antagonist CPP with L-Dopa in Models of Parkinson s Disease.", JOURNAL OF NEURAL TRANSMISSION. PARKINSONS DISEASE AND DEMENTIA SECTION., vol. 3, no. 3, 1991, pages 203 - 213, XP000973350Non-patent––Search report–